- Home
- GNTA vs BMEA Comparison
GNTA vs BMEA Comparison
Compare GNTA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- BMEA
- Stock Information
- Founded
- GNTA 2014
- BMEA 2017
- Country
- GNTA Italy
- BMEA United States
- Employees
- GNTA N/A
- BMEA N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- BMEA Health Care
- Exchange
- GNTA Nasdaq
- BMEA Nasdaq
- Market Cap
- GNTA 70.8M
- BMEA 65.8M
- IPO Year
- GNTA 2021
- BMEA 2021
- Fundamental
- Price
- GNTA $4.49
- BMEA $1.55
- Analyst Decision
- GNTA Strong Buy
- BMEA Strong Buy
- Analyst Count
- GNTA 1
- BMEA 11
- Target Price
- GNTA $25.00
- BMEA $27.60
- AVG Volume (30 Days)
- GNTA 2.7K
- BMEA 691.4K
- Earning Date
- GNTA 01-01-0001
- BMEA 05-05-2025
- Dividend Yield
- GNTA N/A
- BMEA N/A
- EPS Growth
- GNTA N/A
- BMEA N/A
- EPS
- GNTA N/A
- BMEA N/A
- Revenue
- GNTA N/A
- BMEA N/A
- Revenue This Year
- GNTA N/A
- BMEA N/A
- Revenue Next Year
- GNTA N/A
- BMEA N/A
- P/E Ratio
- GNTA N/A
- BMEA N/A
- Revenue Growth
- GNTA N/A
- BMEA N/A
- 52 Week Low
- GNTA $2.79
- BMEA $1.29
- 52 Week High
- GNTA $7.28
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- GNTA 59.43
- BMEA 45.03
- Support Level
- GNTA $4.25
- BMEA $1.29
- Resistance Level
- GNTA $5.98
- BMEA $1.52
- Average True Range (ATR)
- GNTA 0.25
- BMEA 0.14
- MACD
- GNTA 0.01
- BMEA 0.02
- Stochastic Oscillator
- GNTA 19.02
- BMEA 48.96
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.